Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.


Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.
The ACR’s Advocacy 101 course will be held Sept. 24 in Washington, D.C. The course is an interactive, intensive, full-day opportunity for fellows in training and program directors to learn about and become inspired to advocate for the continued strength of rheumatology recruitment and support for education, research and clinical practice. Course applications will be…
Susan Cornwell & Richard Cowan |
WASHINGTON (Reuters)—Republican leaders were in a fierce push on Tuesday to shore up support for a healthcare bill in the U.S. Senate after the nonpartisan Congressional Budget Office said 22 million Americans would lose insurance over the next decade under the measure. Vice President Mike Pence is expected to travel to Capitol Hill on Tuesday…

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

Are you a physician with a patient who no longer requires medical treatment? Do you have a patient you believe would be better served by another physician, specialist or practice due to a developing condition? Do you want to terminate a patient relationship because it is costing more than it is worth to your practice?…

Elizabeth Hofheinz, MPH, MEd |
At present, the U.S. has approximately 5,000 full-time adult rheumatologists. By the year 2025, that number will decline to roughly 3,600.1 Sounds dire, right? Hold that thought. Question: What country has 99 million people and no adult rheumatologists? Answer: Ethiopia.2 The Nigerian Story And then there is Africa’s most populous country, Nigeria, with roughly 170…

When he worked for a multi-specialty practice, Jonathan M. Greer, MD, FACR, FACP, president, Arthritis and Rheumatology Associates of Palm Beach, and affiliate clinical professor of medicine, Nova Southeastern University, Boynton Beach, Fla., found that there were too many restrictions and controls and no way to enhance the revenue stream for rheumatologists. So he moved on…
The second annual ACR Division Directors’ Conference took place in Chicago on March 10–11. The conference opened with a presentation on the use of the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry in academic medical centers by Salahuddin “Dino” Kazi, MD, from UT Southwestern Medical Center, and Jinoos Yazdany, MD, MPH, from the University of California…